Progress on relationship between epigenetic modification and acute myeloid leukemia
-
Abstract: Acute myeloid leukemia (AML) is a rather common disease, which is characterized by proliferation of impaired-function hematopoietic progenitor cells. In tradition standpoint, AML had been considered a genetic-alteration disease, but more and more experimental evidence showed that epigenetic modifications would play an important role in the development and maintenance of leukemia cells. In this article, we summarized the relationship of epigenetic alterations and acute myeloid leukemia.
-
Key words:
- acute myeloid leukemia /
- epigenetic modifications
-
-
[1] Sabattini E, Bacci F, Sagramoso C, et al.WHO classification of tumours of haematopoietic and lymphoid tissues in 2008:an overview[J]. Pathologica,2010,102:83-87.
[2] Yao H, Duan M, Lin L, et al. TET2 and MEG3 promoter methylation is associated with acute myeloid leukemia in a Hainan population[J]. Oncotarget, 2017,8:18337-18347.
[3] Zhao WH, Meng FY, Lai YR, et al.Promoter methylation and expression of death-associated protein kinase gene in acute leukemia[J]. Nan Fang Yi Ke Da Xue Xue Bao, 2017,37:407-410.
[4] Iwama A. Deregulated polycomb complex function in the pathogenesis of MDS[J]. Rinsho Ketsueki, 20,58:654-660.
[5] Brunetti L, Gundry MC, Goodell MA. DNMT3A in Leukemia[J]. Cold Spring Harb Perspect Med, 2017,7.
[6] Pan H, Bilinovich SM, Kaur P,et al. CpG and methylation-dependent DNA binding and dynamics of the methylcytosine binding domain 2 protein at the single-molecule level[J]. Nucleic Acids Res, 2017, 45:9164-9177.
[7] Bird A. DNA methylation patterns and epigenetic memory[J]. Genes Deve, 2002,16:6-21.
[8] Uehara E, Takeuchi S, Yang Y, et al.Aberrant methylation in promoter-associated CpG islands of multiple genes in chronic myelogenous leukemia blast crisis[J]. Oncol Lett, 2012, 3:190-192.
[9] Zhou JD, Zhang TJ, Li XX, et al. Epigenetic dysregulation of ID4 predicts disease progression and treatment outcome in myeloid malignancies[J]. J Cell Mol Med, 2017, 21:1468-1481.
[10] Zhao X, Tian X, Kajigaya S, et al.Epigenetic landscape of the TERT promoter:a potential biomarker for high risk AML/MDS[J]. Br J Haematol, 2016,175:427-439.
[11] Suganuma T, Workman JL.Signals and combinatorial functions of histone modifications[J]. Annu Rev Biochem, 2011, 80:473-499.
[12] Neumann H, Hancock SM, Buning R,et al. A method for genetically installing site-specific acetylation in recombinant histones defines the effects of H3 K56 acetylation[J]. Molecular Cell,2009,36:153-163.
[13] Müller BM,Jana L, Kasajima A,et al. Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer -overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression[J]. BMC Cancer, 2013,13:215.
[14] Daifu T,Kato I, Kozuki K,et al.The clinical utility of genetic testing for t(8;16)(p11;p13) in congenital acute myeloid leukemia[J]. J Pediatr Hematol Oncol, 2014,36:e325-327.
[15] Li Y, Ning Q, Shi J, et al.A novel epigenetic AML1-ETO/THAP10/miR-383 mini-circuitry contributes to t(8;21) leukaemogenesis[J]. EMBO Mol Med,20179:933-949.
[16] Šustková Z, áulen M, Semerád L,et al.New Drugs in the Treatment of Acute Myeloid Leukemia in the Elderly[J].Klin Onkol, 2017,30:190-196.
[17] Young CS, Clarke KM, Kettyle LM, et al. Decitabine-Vorinostat combination treatment in acute myeloid leukemia activates pathways with potential for novel triple therapy[J]. Oncotarget, 2017, 19,8:51429-51446.
[18] Oka S, Ono K, Nohgawa M. Nohgawa, Successful treatment with azacitidine for the simultaneous occurrence of multiple myeloma and acute myeloid leukemia with concomitant del(5q) and the JAK2 V617F mutation[J]. Ann Hematol, 2017,96:1411-1413.
[19] Li Y, Zhao K, Yao C, et al. Givinostat, a type II histone deacetylase inhibitor, induces potent caspase-dependent apoptosis in human lymphoblastic leukemia[J]. Genes Cancer, 2016,7:292-300.
[20] Federico M, Bagella L. Histone deacetylase inhibitors in the treatment of hematological malignancies and solid tumors[J]. J Biomed Biotechnol, 2011:475641.
-
计量
- 文章访问数: 100
- PDF下载数: 22
- 施引文献: 0
下载: